Skip to content

News · Japan regulation

Nipro's Stemirac converts from conditional approval in Japan

· Sources: 1 · Translated from the Japanese edition

Photo: Toon Lambrechts / Unsplash

Nipro said on November 16, 2026 that MHLW had granted marketing approval for Stemirac injection, the regenerative medical product it developed with Sapporo Medical University, on the same day. The product already held conditional, time-limited approval, and this is the renewed approval that follows it. Nipro says it is the first case in Japan of a product going from conditional, time-limited approval to full approval, by its own survey as of November 16, 2026.

An autologous bone marrow MSC infusion for spinal cord injury

Stemirac is an autologous cell-processed product. Bone marrow is taken from the patient, mesenchymal stem cells are expanded from it, and the cells are returned by intravenous infusion. The indication filed was improvement of neurological symptoms and functional impairment associated with spinal cord injury.

It received conditional, time-limited approval in December 2018. That route lets a product be sold once efficacy can be inferred rather than confirmed, with conditions attached and a time limit of up to seven years, and requires the sponsor to apply again inside that window. This approval answers that second application.

GCTP compliance was an approval requirement under the conditional route too

What the conditional route relaxes is narrow. PMD Act Article 23-26(1) sets aside only the parts of Article 23-25(2)(iii) at (a) and (b), efficacy and markedly harmful effects, so those can be presumed rather than found. Article 23-25(2)(iv), which withholds approval unless the site's manufacturing control and quality control meet the standard set by MHLW ordinance, is not set aside, and so it applied under the conditional approval as well.

That standard is GCTP, the Ministerial Ordinance on Standards for Manufacturing Control and Quality Control of Regenerative Medical Products (MHLW Ordinance No. 93 of 2014). Under Article 23-25(6), the site is inspected for compliance when the holder applies for an approval, and then at intervals set by Cabinet Order of not less than three years, by document review or on site.

A precedent for the five products still inside their window

Eight regenerative medical products had received conditional, time-limited approval in Japan as of October 2026, Stemirac among them. Five are still inside their window. Of those that reached the end of it, HeartSheet was refused full approval and the application for Collategene was withdrawn; both left the market in 2024.

For a sponsor holding one of the remaining five, there is now a case that went through the second application and came out with an approval.

What to check after a conversion like this

How the approval conditions were restated is the first item, and the approval document and the review report are where it shows. For a product whose material cannot be re-made, a change to the process or the specifications raises the question of what the new output is compared against. Splitting one patient's material between the old and the new process is one way to get a comparison, and how the material is split is settled before the change, not after.

For anyone manufacturing under contract or supplying materials, the license category of the site and the timing of the next GCTP compliance inspection are worth confirming. Release is the other constraint that does not change with the approval: an autologous product is one lot for one patient, and the final sterility result can arrive after the dose has been given. On the contract side, S-RACMO has signed a definitive deal for Takara Bio's GMP cell processing business.

Sources

  1. Marketing approval obtained for the regenerative medical product STEMIRAC injection (Japanese, PDF). Nipro Corporation, Nov 2026.

Read this story in Japanese